- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04394286
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
May 17, 2022 updated by: Baxalta now part of Shire
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
The purpose of this study is to evaluate the safety and dose escalation of SHP648 an adeno-associated viral vector for gene transfer in hemophilia B participants.
Study Overview
Detailed Description
This study will consists of 3 dose cohorts with 2-7 participants in each of the three ascending dose cohorts.
Initially 2 participants will be dosed in Cohort 1, followed by dosing of up to 5 additional participants if the cohort is expanded.
Participants in cohort 2 and 3 will receive 2-fold or 3-fold dose escalation to their respective preceding cohort doses if required.
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male, aged 18 to 75 years at the time of screening.
- Established severe or moderately severe hemophilia B (plasma FIX activity lesser than or equal to [<=] 2 percent (%) measured following greater than or equal to [>=] 5 half-lives of most recent exposure to exogenous FIX) and either >= 3 hemorrhages per year requiring treatment with exogenous FIX or use of prophylactic therapy.
- History of greater than (>) 50 exposure days to exogenously administered FIX concentrates or cryoprecipitates.
- Sexually active men must agree to use barrier contraception (combination of a condom and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized, or contraception-practicing partners for a minimum of 6 months after administration of SHP648, or until SHP648 genomes are no longer detected in the semen (whichever is sooner).
- Signed informed consent.
Exclusion Criteria:
- Bleeding disorder(s) other than hemophilia B.
- Documented laboratory evidence of having developed inhibitors (>= 0.6 Bethesda Units [BU] on any single test) to FIX proteins at any time.
- Documented prior allergic reaction to any FIX product.
- Anti-AAV8 neutralizing antibody titer >= 1:5.
- Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.
- Having a disease in which treatment with prednisolone or prednisone is not tolerated (including, but not limited to osteoporosis with vertebral fractures, severe labile hypertension, and brittle diabetes).
Evidence of markers of potential underlying risk for autoimmune mediated hepatic disease:
- Anti-smooth muscle antibody (ASMA) titer >= 1:40. Values of 1:31 to 1:39 will be flagged as possibly abnormal and the Investigator and Medical Monitor will evaluate the participant for eligibility
- Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers
- Total Immunoglobulin G (IgG) > 1.5x upper limit of normal (ULN)
- Antinuclear antibody (ANA) titer > 1:320 OR ANA titer > 1:80 if demonstrated concurrently with alanine aminotransferase (ALT) that is > ULN
- Active Hepatitis C: as indicated by detectable hepatitis C virus ribonucleic acid (HCV RNA) by polymerase chain reaction (PCR).
- Hepatitis B: If surface hepatitis B virus (HBV) antigen is positive.
- Receiving chronic systemic antiviral and/or interferon therapy within 4 weeks prior to enrollment.
- Clinically significant infections (e.g., systemic fungal infections) requiring systemic treatment.
- Known immune disorder (including myeloma and lymphoma).
- Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or other disorders.
- An absolute neutrophil count lesser than < 1000 cells per cubic millimetre (cells/mm^3).
Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the following:
- Platelet count < 150,000/microliter (μL)
- Albumin <= 3.5 gram per deciliter (g/dL)
- Total bilirubin > 1.5x ULN and direct bilirubin >= 0.5 milligram per deciliter (mg/dL)
- ALT or Aspartate aminotransferase (AST) > 1.0x ULN
- Alkaline phosphatase > 2.0x ULN
- History of liver biopsy or imaging indicating moderate or severe fibrosis (Metavir staging of F2 or greater)
- History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy
- FibroSURE Score >= 0.4
- Prothrombin time international normalized ratio (INR) >= 1.4
- Serum creatinine > 1.5 mg/dL.
- Human immunodeficiency virus (HIV) if cluster of differentiation 4 (CD4)+ cell count <= 200 mm^3 and/or viral load > 20 copies per milliliter (copies/mL).
- Urine protein > 30 mg/dL.
- Body mass index > 38.
- Orthopedic or other major surgery planned within 6 months after enrollment.
- Acute or chronic disease that, in the opinion of the Investigator, would adversely affect participant safety or compliance or interpretation of study results.
- Received an AAV vector previously or any other gene transfer agent in the previous 12 months prior to Study Day 0.
- Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease).
- History of arterial or venous thrombosis / thromboembolism, or a known pro-thrombotic condition.
- Recent history of psychiatric illness or cognitive dysfunction (including drug or alcohol abuse) that, in the opinion of the Investigator, is likely to impair participants ability to comply with protocol mandated procedures.
- Participation in another study involved with an investigational agent.
- Participant is family member or employee of the Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1
Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).
|
Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
Other Names:
|
EXPERIMENTAL: Cohort 2
Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).
|
Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
Other Names:
|
EXPERIMENTAL: Cohort 3
Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).
|
Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With SHP648 Related Serious and Non- Serious Adverse Events (AEs)
Time Frame: From study start date to Month 12
|
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this investigational product (IP) or medicinal product.
A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly.
|
From study start date to Month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Factor IX (FIX) Levels Before and After SHP648 Infusion
Time Frame: From study start date to Month 12
|
Plasma FIX levels before and after SHP648 infusion were planned to be reported.
|
From study start date to Month 12
|
Annualized Bleed Rate (ABR) Before and After SHP648 Infusion
Time Frame: From study start date to Month 12
|
ABR was to be assessed based upon each individual bleeding episode.
A bleed episode was defined as subjective (example, pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FIX.
ABR before and after SHP648 administration was planned to be reported.
|
From study start date to Month 12
|
Number of Participants With Positive Binding Antibody Titers to Adeno-Associated Virus (AAV8)
Time Frame: From study start date to Month 12
|
Number of participants with positive binding antibodies titers to AAV8 was planned to be reported.
|
From study start date to Month 12
|
Number of Participants With Positive Neutralizing Antibody Titers to AAV8
Time Frame: From study start date to Month 12
|
Number of participants with positive neutralizing antibodies to AAV8 was planned to be reported.
|
From study start date to Month 12
|
Number of Participants With T-cell Response to AAV8
Time Frame: From study start date to Month 12
|
Number of participants with T-cell response to AAV8 was planned to be reported.
|
From study start date to Month 12
|
Number of Participants With T-cell Response to FIX Transgene Products
Time Frame: From study start date to Month 12
|
Number of participants with T-cell response to FIX transgene products was planned to be reported.
|
From study start date to Month 12
|
Duration of SHP648 Genomes Present in Bodily Fluids
Time Frame: From study start date to Month 12
|
Duration of SHP648 genomes present in bodily fluids such as serum, blood, saliva, urine, stool, and semen was planned to be reported.
|
From study start date to Month 12
|
Percent Change in Consumption of FIX Before and After Gene Transfer
Time Frame: From study start date to Month 12
|
Percent change in consumption of exogenous FIX before and after gene transfer was planned to be reported.
|
From study start date to Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 13, 2020
Primary Completion (ACTUAL)
May 3, 2021
Study Completion (ACTUAL)
May 3, 2021
Study Registration Dates
First Submitted
May 15, 2020
First Submitted That Met QC Criteria
May 15, 2020
First Posted (ACTUAL)
May 19, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 19, 2022
Last Update Submitted That Met QC Criteria
May 17, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHP648-101
- 2018-004024-11 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia B
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
BayerCompletedHemophilia A; Hemophilia BIsrael
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
University College, LondonRecruiting
-
University of British ColumbiaBiogenCompletedHemophilia A, Congenital | Hemophilia B, CongenitalCanada
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
-
Suzhou Alphamab Co., Ltd.RecruitingHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
-
AryoGen Pharmed Co.CompletedHemophilia A With Inhibitor | Hemophilia B With InhibitorIran, Islamic Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHemophilia A With Inhibitor | Hemophilia B With InhibitorChina